Journal: Stem Cells Translational Medicine

Article Title: Bone Morphogenetic Protein‐6 Attenuates Type 1 Diabetes Mellitus‐Associated Bone Loss

doi: 10.1002/sctm.18-0150

Figure Lengend Snippet: Transcript or protein expression of endogenous growth factors and their receptors and downstream signaling molecules of type 1 diabetes mellitus (T1DM)‐ and non‐T1DM‐bone marrow‐derived mesenchymal stem cells (BMSCs). (A): Expression levels of BMP s and TGFB s in T1DM‐BMSCs during osteogenic induction were compared with those in non‐T1DM‐BMSCs. (B): Expression levels of transcripts of BMP6 receptors HJV, ACVR1, ACVR2A, ACVR2B, BMPR1A, and BMPR1B in T1DM‐BMSCs during osteogenic induction were compared with those in non‐T1DM‐BMSCs. (C): Expression levels of BMPR2 and TGFBR2 and their downstream signaling SMADs and phospho‐SMADs in T1DM‐BMSCs during osteogenic induction were compared with those in non‐T1DM‐BMSCs. * p < .05; n = 3 technical replicates.

Article Snippet: To determine if BMP6 is a target molecule of interest involved in the regulation of osteogenesis of T1DM‐ or non‐T1DM‐BMSCs, the cell in osteogenic culture was supplemented with or without 10 ng/ml of recombinant BMP6 or neutralized with or without 2 μg/ml of BMP6 antibody (R&D, Minneapolis, MN).

Techniques: Expressing, Derivative Assay

Journal: Stem Cells Translational Medicine

Article Title: Bone Morphogenetic Protein‐6 Attenuates Type 1 Diabetes Mellitus‐Associated Bone Loss

doi: 10.1002/sctm.18-0150

Figure Lengend Snippet: Osteogenesis of type 1 diabetes mellitus (T1DM)‐ and non‐T1DM‐bone marrow‐derived mesenchymal stem cells (BMSCs) modulated by receptor antagonists. (A): Quantification and cytological staining of alkaline phosphatase activity of the cell treated with dorsomorphin (DOR), a bone morphogenetic protein receptor antagonist, and/or SB431542 (SB), a transforming growth factor‐β receptor antagonist during osteogenesis. (B): Quantification of calcium content and cytological staining of alizarin red to detect matrix mineralization in BMSC culture treated with or without DOR and/or SB during osteogenic induction. (C): Amounts of soluble BMP6 in T1DM‐ and non‐T1DM‐BMSC culture. Concentration levels of BMP6 released from the cell in the cultured medium detected by ELISA during osteogenesis induction. * p < .05; n = 3 biological replicates, values represented as mean ± SEM. Scale bar: 100 μm.

Article Snippet: To determine if BMP6 is a target molecule of interest involved in the regulation of osteogenesis of T1DM‐ or non‐T1DM‐BMSCs, the cell in osteogenic culture was supplemented with or without 10 ng/ml of recombinant BMP6 or neutralized with or without 2 μg/ml of BMP6 antibody (R&D, Minneapolis, MN).

Techniques: Derivative Assay, Staining, Activity Assay, Concentration Assay, Cell Culture, Enzyme-linked Immunosorbent Assay

Journal: Stem Cells Translational Medicine

Article Title: Bone Morphogenetic Protein‐6 Attenuates Type 1 Diabetes Mellitus‐Associated Bone Loss

doi: 10.1002/sctm.18-0150

Figure Lengend Snippet: Osteogenesis of type 1 diabetes mellitus (T1DM)‐ and non‐T1DM‐bone marrow‐derived mesenchymal stem cells (BMSCs) treated with or without bone morphogenetic protein‐6 (BMP6) or BMP6‐neutralizing antibody. (A): Cytological staining and quantification of corresponding alkaline phosphatase (ALP) activity and calcium content. (B): Expression levels of CBFA1 and OPN transcripts. (C): Cytological staining and quantification of corresponding ALP activity and calcium content. (D): Expression levels of CBFA1 and OPN transcripts. n = 3 biological replicates, values represented as mean ± SEM. Scale bar: 100 μm.

Article Snippet: To determine if BMP6 is a target molecule of interest involved in the regulation of osteogenesis of T1DM‐ or non‐T1DM‐BMSCs, the cell in osteogenic culture was supplemented with or without 10 ng/ml of recombinant BMP6 or neutralized with or without 2 μg/ml of BMP6 antibody (R&D, Minneapolis, MN).

Techniques: Derivative Assay, Staining, Activity Assay, Expressing

Journal: Stem Cells Translational Medicine

Article Title: Bone Morphogenetic Protein‐6 Attenuates Type 1 Diabetes Mellitus‐Associated Bone Loss

doi: 10.1002/sctm.18-0150

Figure Lengend Snippet: Treatment of bone loss in streptozotocin (STZ)‐induced diabetic mice by bone morphogenetic protein‐6 (BMP6). (A): Experimental design illustrating time points for inducing diabetes by STZ, establishing bone loss, and treating bone loss by BMP6 administration in the animal model as well as for performing a number of analyses. (B): Serum levels of BMP6 in animals with or without STZ induction determined by ELISA. (C): Bone mineral density in femur of mice induced with or without STZ and then treated with or without BMP6. * p < .05; n = 6 biological replicates, values represented as mean ± SEM.

Article Snippet: To determine if BMP6 is a target molecule of interest involved in the regulation of osteogenesis of T1DM‐ or non‐T1DM‐BMSCs, the cell in osteogenic culture was supplemented with or without 10 ng/ml of recombinant BMP6 or neutralized with or without 2 μg/ml of BMP6 antibody (R&D, Minneapolis, MN).

Techniques: Animal Model, Enzyme-linked Immunosorbent Assay